ICRR 2027 **20 - 25 June 2027** **Brno, Czech Republic**

RESILIENCE
Framework Partnership Agreement (FPA)

COUNTERACT
EUROPEAN AGILE NETWORK FOR MEDICAL COUNTERMEASURES AGAINST CBRN THREATS

Funded by the European Union

Coordinated by CEA

Symposium **R&D on Radiological and Nuclear Medical Counter Measures: insights from European Defense Fund projects**

Organisers *Michael Abend & Yannick Saintigny*

Date *xx June 2027*

Hour	Name		Organism	Member-State	e-mail	Title	Related to EDF funded project (and HERA/EU4H)
	Last	First					
	Introduction						
14:00	**Saintigny**	Yannick	CEA	France	*yannick.saintigny@cea.fr*	*Strategy, objectives and ecosystem of the FPA Resilience. Symposium structure*	Resilience FPA, Resilience D 2025, Resilience R 2026, Counteract, (Tesar)
	Estimating the radiation exposure in the battle field						
14:15	**Benderitter**	Marc	ASNR	France	*marc.benderitter@asnr.fr*	*Operational dosimetric evaluation of healthy soldiers*	Resilience D 2024
	Predicting ACUTE clinical health effects (ARS severity degree) after radiation exposure						
14:35	**Abend**	Michael	BIR	Germany	*mabend3901@aol.com*	*Introduction into radiation research and devlopment for medical countermasures*	Resilience R 2023, Counteract
14:50	**Stewart**	Samantha	BIR	Germany	*samanthastewart@bundeswehr.org*	*Point of care diagnostic of the ARS severity degree using gene expression based microfluidic cards*	Resilience R 2023
15:10	**Bayens**	Ans	University of Gent	Belgium	*ans.baeyens@ugent.be*	*Using cytogenetic assays for diagnosis of ARS severity degrees*	Resilience R 2023
	Examinig potential therapeutic targets for late clinical health effects after radiation exposure						
15:30	**Ziegler**	Joshua	University of Mainz	Germany	*joshua.ziegler@uni-mainz.de*	*Transcriptomic analysis on Chernobyl victims: Examinations for persistent radiation exposure related changes of the transcriptome and their as*	Resilience R 2023
	Development of MCM against radionuclides contamination						
15:50	**Reinholds**	Ingars	University of Latvia	Latvia	*ingars.reinholds@lu.lv*	*Decorporation and human decontamination agents for RN threats 1/2*	Resilience R 2023, Resilience D 2026
16:10	**Muiznieks**	Indrikis	University of Latvia	Latvia	*indrikis.muiznieks@lu.lv*	*Decorporation and human decontamination agents for RN threats 2/2*	Resilience R 2023, Resilience D 2026
16:30	**Coffee break**						
	Developing relevant animal models for MCM against ARS and radio-combined injuries						
17:00	**Jullien**	Nicolas	IRBA	France	*nicolas.jullien@intradef.gouv.fr*	*Development of in vivo combined models for MCM safety and efficacy assements for radio-combined injuries*	Resilience D 2025
17:20	**Tichý**	Aleš	UNOB	Czech Republic	*ales.tichy@unob.cz*	*In vivo models and relevant biological parameters for testing the efficacy of candidate molecules against ARS*	Resilience D 2025, Counteract
	Potential of stem cell therapies for treatment of ARS						
17:40	**Chapel**	Alain	ASNR	France	*alain.chapel@asnr.fr*	*New approaches for human stem cell protection following irradiation*	Resilience D 2025
18:00	**Peltzer**	Juliette	IRBA	France	*juliette.peltzer@inserm.fr*	Development of Extra-cellular Vesicles ready-to-use therapies for mass casualty management.	Resilience D 2025
	Further therapeutic and preventive strategies to counteract RN threats						
18:20	**Gauthier**	Laurent	CEA	France	*laurent-r.gauthier@cea.fr*	*New therapeutic management strategies of central nervous system ARS.*	Resilience R 2026
18:40	**Moreno**	Stéphanie	CEA	France	*stephanie.moreno@cea.fr*	*A Novel Autonomous Cyto-Protective Strategy: Preventive and Therapeutic Effects on Survival and Regeneration Post-Irradiation*	Resilience R 2026, (Tesar)
19:00	**Le Grand**	Bruno	Usil Therapeutics	Luxembourg	*bruno@usil-therapeutics.com*	*Development of a universal, cost-effective, easy-to-use medical countermeasure for RN threats*	Resilience R 2026, (Tesar)

0:15 Introduction
0:20 Presentation: 15 minutes + questions: 5 minutes
0:30 Coffee break
5:00 Total lengh